动脉高血压和高血压介导的器官损伤在抗癌治疗的心脏毒性中的作用。

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Giacomo Tini, Giuliano Tocci, Allegra Battistoni, Matteo Sarocchi, Camilla Pietrantoni, Domitilla Russo, Beatrice Musumeci, Carmine Savoia, Massimo Volpe, Paolo Spallarossa
{"title":"动脉高血压和高血压介导的器官损伤在抗癌治疗的心脏毒性中的作用。","authors":"Giacomo Tini,&nbsp;Giuliano Tocci,&nbsp;Allegra Battistoni,&nbsp;Matteo Sarocchi,&nbsp;Camilla Pietrantoni,&nbsp;Domitilla Russo,&nbsp;Beatrice Musumeci,&nbsp;Carmine Savoia,&nbsp;Massimo Volpe,&nbsp;Paolo Spallarossa","doi":"10.1007/s11897-023-00590-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of the review: </strong>Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients.</p><p><strong>Recent findings: </strong>Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977700/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.\",\"authors\":\"Giacomo Tini,&nbsp;Giuliano Tocci,&nbsp;Allegra Battistoni,&nbsp;Matteo Sarocchi,&nbsp;Camilla Pietrantoni,&nbsp;Domitilla Russo,&nbsp;Beatrice Musumeci,&nbsp;Carmine Savoia,&nbsp;Massimo Volpe,&nbsp;Paolo Spallarossa\",\"doi\":\"10.1007/s11897-023-00590-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of the review: </strong>Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients.</p><p><strong>Recent findings: </strong>Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.</p>\",\"PeriodicalId\":10830,\"journal\":{\"name\":\"Current Heart Failure Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977700/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Heart Failure Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11897-023-00590-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-023-00590-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

综述的目的:动脉高血压(AH)是社区和肿瘤患者中最常见的心血管(CV)危险因素。它也代表了最重要的心血管疾病易患抗癌治疗相关的心脏毒性。在存在心脏ah介导的器官损伤(HMOD)时,这种风险增加。将回顾AH和HMOD对心脏毒性发展的影响,重点关注肿瘤患者的具体情况和管理意义。最近的研究发现:在抗癌治疗之前或期间没有充分控制AH和/或在治疗期间或完成后AH的发展对肿瘤患者的临床病程有不利影响,特别是如果存在HMOD。由于忽视心血管健康可能危及抗癌治疗的成功,临床医生照顾肿瘤患者的目标应该包括AH和HMOD的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.

Purpose of the review: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients.

Recent findings: Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Heart Failure Reports
Current Heart Failure Reports Medicine-Emergency Medicine
CiteScore
5.30
自引率
0.00%
发文量
44
期刊介绍: This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信